Open AccessSTUDY ON ANTIVIRAL DRUGS RAISENEW HOPES FOR RECOVERY ON SARS-COV-2
Author(s) -
Chaitanya Krishna Kommineni,
Krishna Keethika Oruganti,
Narasimha Vakkalagadda,
Venkata Sai Yogesh Konakandla,
Divya Kumari Muppa,
Kumudwati Kakani,
Sai Neeraj Krishna Vedantam,
Praveen Kumar Vemuri
Publication year - 2022
Publication title -
international journal of advanced research
Language(s) - English
Resource type - Journals
ISSN - 2320-5407
DOI - 10.21474/ijar01/14513
Subject(s) - druggability , virology , pandemic , covid-19 , transmission (telecommunications) , antiviral drug , virus , medicine , viral life cycle , drug , intensive care medicine , biology , disease , infectious disease (medical specialty) , viral replication , pharmacology , computer science , telecommunications , biochemistry , pathology , gene
The goal of this study is to perform a systematic assessment of the literature to determine the effectiveness and safety of molnupiravir and paxlovid oral antiviral drugs in COVID-19 patients.These Drugs has shown consistent efficacy against the SARS-CoV-2 viruss Gamma, Delta, and Mu versions, the firm has yet to release data on the drugs action against Omicron. COVID-19, a worldwide pandemic produced by the SARS-CoV-2 virus, has already wreaked havoc on human life and the global economy. In this study, an attempt is made to comprehend the SARS-CoV-2 life cycle, and prospective druggable targets against SARS-CoV-2 are outlined based on this knowledge. COVID-19, there are more vaccine candidates in the pipeline at the same time than there haveever been for an infectious illness. Theyre all attempting to accomplish the same goal: viral immunity, and some may even be able to block transmission. Whole virus, protein subunit, viral vector, and nucleic acid are the four types of vaccines now being tested in clinical studies.